Corrigendum to "Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births".

[This corrects the article DOI: 10.1155/2017/2810202.].

In the article titled “Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births” [1], the authors discovered some discrepancies in the data which were used in the article. Thus, the authors repeated the analyses with the correct data. There was a slightly lower incidence of HELLP (4 in total of which 3 in the non-HCQ group) instead of 6 in total (of which 5 in the non-HCQ group), but statistical significance was similar. Other outcomes were unchanged.

Corrected Table 2 is shown below.

Table 2

Maternal and fetal pregnancy outcome according to HCQ treatment.

	Total (N = 110)	Non-HCQ (N = 80)	HCQ (N = 30)	OR (95% CI) $$; p value
Maternal outcome
Preeclampsia∗	11 (10.9)	9 (11.3)	2 (6.7)	1.0 (1.0-1.0); 0.997
Eclampsia∗	0 (0)	0 (0)	0 (0)	—
(i) HELLP∗	4 (3.6)	3 (3.8)	1 (3.3)	0.93
Prednisone use†	63 (57.3)	45 (56.3)	18 (60.0)	0.9 (0.7-1.2); 0.35
Prednisone < 7.5 mg within prednisone users	36 (32.7)	14 (17.5)	22 (73.3)	0.2 (0.0-1.4); 0.10
Fetal outcome
Early spontaneous abortion (<10 weeks of gestation)	19 (17.3)	10 (12.5)	9 (30.0)▲	1.5 (0.3-9.0); 0.66
Fetal death‡ (>10 weeks of gestation)	3 (2.7)	2 (2.5)	1 (3.3)	-
Preterm live birth	18 (16.4)	16 (20.0)	2 (6.7)	0.5 (0.1-2.4); 0.37
Of which <34 weeks	5 (4.5)	5 (6.3)	0 (0)	-
Term live birth	70 (63.6)	52 (65.0)	18 (60.0)	0.9 (0.3-2.7); 0.90
Small for gestational age	15 (13.6)	10 (12.5)	5 (16.7)	2.2 (0.6-7.5); 0.22
				β (95% CI)$$; p value
Duration of pregnancy∗ (median, IQR)	38.9 (37.1-40.0)	38.9 (36.4-40.1)	38.7 (37.7-39.4)	-1 (-3.8-1.8); 0.48
Duration of pregnancy in preterm live births# (median, IQR)	35.1 (31.5-36.3)	34.9 (30.9-35.4)	36.8 (36.7-..)	2.4 (1.0-3.8); 0.001

Data depicted as numbers (%) unless otherwise indicated. HCQ: hydroxychloroquine; IQR: interquartile range; HELLP: (incomplete) hemolysis, elevated liver enzymes, and low platelet syndrome. $$Dependent variable: pregnancy outcome/prednisone use/duration of pregnancy. Predictor variable: HCQ use (ref = non-HCQ). Adjusted for antiphospholipid status, except for early spontaneous abortion. ∗Pregnancies ending <10 weeks of gestation were excluded [N = 89/68/21]. †Prednisone dose was increased in 4.6% of pregnancies. ▲Of which 5 occurred within one woman. ‡Two were due to elective termination one because of trisomy 21 with Fallot's tetralogy and one because of infaust prognosis with severe preeclampsia, both occurred within the non-HCQ group. #[N = 18/16/2], duration of pregnancy in weeks.

Additionally, the email address of the corresponding author should be changed to “s.kroese@hagaziekenhuis.nl.”

The authors confirm that this does not affect the results and conclusions of the article, and the editorial board agrees to the publication of a corrigendum.